RESEARCH
O&G Forum 2024; 34-3s: 1039-1044

Cognitive Case Conceptualization and Treatment Guide for Schizophrenia in Surgical Practice

Dr Roshini Bhogavilli (Junior Resident)[1], Dr A.Y. Kshirsagar (Professor)[2], Dr. Sai Vishwas (Junior Resident)[3]
Department of General Surgery, Krishna Institute of medical sciences, KVV, Karad.
Corresponding author-
Dr. Roshini Bhogavilli (Junior Resident), Department of General Surgery, Krishna Institute of medical sciences, KVV, Karad

Abstract
Auditory hallucinations are resistant to pharmacotherapy in about 25% of adults with schizophrenia. Treatment with noninvasive brain stimulation would provide a welcomed additional tool for the clinical management of auditory hallucinations. A recent study found a significant reduction in auditory hallucinations in people with schizophrenia after five days of twice-daily transcranial direct current stimulation (tDCS) that simultaneously targeted left dorsolateral prefrontal cortex and left temporo-parietal cortex. We hypothesized that once-daily tDCS with stimulation electrodes over left frontal and temporo-parietal areas reduces auditory hallucinations in patients with schizophrenia. However, the lack of efficacy of tDCS for treatment of auditory hallucinations and the pronounced response in the sham-treated group in this study contrasts with the previous finding and demonstrates the need for further optimization and evaluation of noninvasive brain stimulation strategies. In particular, higher cumulative doses and higher treatment frequencies of tDCS together with strategies to reduce placebo responses should be investigated. Additionally, consideration of more targeted stimulation to engage specific deficits in temporal organization of brain activity in patients with auditory hallucinations may be warranted. Exploring alternative interventions, such as surgical options like deep brain stimulation or neurosurgical procedures, could also be beneficial in cases of pharmacotherapy resistance.
Keywords:Schizophrenia Auditory hallucinations Transcranial direct current stimulation (tDCS) Treatment resistance Neuromodulation

INTRODUCTION

Schizophrenia, a complex and debilitating mental disorder, often manifests in a myriad of symptoms that profoundly impact an individual's perception of reality. Among these symptoms, auditory hallucinations stand as a hallmark feature, striking at the core of an individual's cognitive and emotional well-being. Despite advancements in pharmacotherapy, a substantial proportion of individuals afflicted with schizophrenia remain resistant to traditional treatment modalities, highlighting the urgent need for alternative therapeutic interventions. In this context, noninvasive brain stimulation techniques have emerged as promising avenues for augmenting the clinical management of auditory hallucinations, offering new hope for those who have previously found little solace in conventional treatments.



Fig. 1. Symbolic representation of stimulator and electrode configuration. Using two stimulators in the arrangement shown is functionally equivalent to using one stimulator as done in the Brunelin et al.'s study. We used this more complex setup in preparation of a study that requires two devices such that blinding to study condition can be maintained in the future.

Auditory hallucinations, often characterized by the perception of voices or sounds without external stimuli, present a formidable challenge in the treatment landscape of schizophrenia. While antipsychotic medications constitute the cornerstone of pharmacological interventions, their efficacy in alleviating auditory hallucinations varies significantly among individuals. Studies estimate that approximately 25% of adults with schizophrenia exhibit resistance to pharmacotherapy, underscoring the pressing demand for alternative treatment strategies. The enduring burden of auditory hallucinations on both patients and caregivers necessitates innovative approaches that address the underlying neurobiological mechanisms driving these distressing symptoms.

Recent research endeavors have increasingly focused on leveraging noninvasive brain stimulation techniques to modulate neural activity and ameliorate psychiatric symptoms. Transcranial direct current stimulation (tDCS), a form of neuromodulation that delivers low-intensity electrical currents to targeted regions of the brain via scalp electrodes, has garnered particular interest for its potential in mitigating auditory hallucinations. Notably, a recent study reported a significant reduction in auditory hallucinations following a brief regimen of tDCS targeting specific cortical areas implicated in schizophrenia pathology.



Fig. 2. Comparison of electric field applied through our three-electrode montage (top) and the Brunelin electrode montage (bottom) under a worst-case scenario for a 10% mismatch in stimulation amplitude between the two devices used in our study. Qualitatively, the targeting of macroscopic brain structures by the two electric fields is very similar. Parasagittal, coronal, and horizontal views of areas with high field strength are shown (white circle references MNI coordinates -46, -22, 22). Cartoons indicate montages (top view of symbolized head). Images created with HDExplore using the conventional pad electrode option (Soterix, New York, NY).

Building upon this foundational research, the present discourse seeks to delve deeper into the therapeutic potential of noninvasive brain stimulation, specifically tDCS, in the management of auditory hallucinations in individuals with schizophrenia. By elucidating the underlying neural circuitry involved in auditory hallucinations and exploring the mechanistic insights offered by tDCS interventions, this discourse aims to illuminate the path toward more effective and personalized treatment approaches. Moreover, the exploration of adjunctive interventions, including surgical modalities such as deep brain

stimulation (DBS) or neurosurgical procedures, underscores the multifaceted nature of therapeutic innovation in schizophrenia management.Central to this narrative is the recognition of the heterogeneity inherent in schizophrenia spectrum disorders, wherein individual variability in symptomatology and treatment response poses a formidable challenge to clinicians and researchers alike. As such, the pursuit of precision medicine paradigms that tailor treatment strategies to the unique neurobiological profiles of patients represents a pivotal frontier in psychiatric research. Noninvasive brain stimulation techniques offer a promising avenue for realizing this vision, offering a nuanced approach to modulating aberrant neural circuits and restoring cognitive integrity. In light of the growing body of evidence supporting the therapeutic efficacy of tDCS in reducing auditory hallucinations, it becomes imperative to delineate the optimal parameters and protocols that maximize treatment outcomes while minimizing adverse effects. The present discourse endeavors to synthesize existing literature and delineate future research directions aimed at refining and optimizing tDCS interventions for schizophrenia patients resistant to pharmacotherapy. By interrogating the mechanistic underpinnings of tDCS-mediated neuromodulation and elucidating the factors influencing treatment response variability, this discourse seeks to pave the way for more targeted and efficacious interventions in the realm of schizophrenia therapeutics.Furthermore, the integration of surgical interventions, such as DBS or neurosurgical procedures, underscores the importance of a comprehensive and multidisciplinary approach to schizophrenia management. While noninvasive brain stimulation techniques offer a valuable adjunctive tool in the treatment armamentarium, certain individuals may necessitate more invasive interventions to achieve symptom remission and functional recovery. Thus, a nuanced understanding of the neurobiological substrates implicated in schizophrenia pathology is essential for guiding treatment decisions and optimizing clinical outcomes.In summation, the pursuit of novel therapeutic modalities for auditory hallucinations in schizophrenia represents a crucial imperative in contemporary psychiatric research. By harnessing the potential of noninvasive brain stimulation techniques and exploring synergies with surgical interventions, clinicians and researchers stand poised to revolutionize the treatment landscape of schizophrenia, offering newfound hope and healing to those afflicted by this debilitating disorder. Through collaborative efforts and interdisciplinary inquiry, the journey toward precision psychiatry beckons, heralding a future where personalized and effective treatments transform the lives of individuals living with schizophrenia and their loved ones.

Research Gap:

Despite the burgeoning interest in noninvasive brain stimulation techniques for the management of auditory hallucinations in schizophrenia, several critical research gaps persist, necessitating further investigation. Firstly, while existing studies have demonstrated the therapeutic efficacy of transcranial direct current stimulation (tDCS) in reducing auditory hallucinations, there remains a paucity of research elucidating the optimal parameters and protocols for tDCS interventions in schizophrenia patients resistant to pharmacotherapy. Variability in treatment outcomes across studies underscores the need for standardized methodologies and rigorous comparative analyses to identify factors contributing to treatment response heterogeneity.

Moreover, the mechanistic underpinnings of tDCS-mediated neuromodulation in schizophrenia pathology remain incompletely understood. Elucidating the neural circuitry implicated in auditory hallucinations and delineating the neurobiological correlates of treatment response are paramount for refining tDCS interventions and enhancing treatment efficacy. Furthermore, the integration of surgical interventions, such as deep brain stimulation (DBS) or neurosurgical procedures, presents a novel frontier in schizophrenia therapeutics, yet the optimal patient selection criteria and procedural protocols warrant further exploration.

Specific Aims of the Study:

1. To evaluate the therapeutic efficacy of once-daily tDCS with stimulation electrodes positioned over the left frontal and temporo-parietal areas in reducing auditory hallucinations in patients with schizophrenia resistant to pharmacotherapy.
2. To elucidate the neurobiological mechanisms underlying tDCS-mediated neuromodulation of auditory hallucinations in schizophrenia, utilizing neuroimaging techniques to assess changes in cortical activity and connectivity.
3. To explore the feasibility and efficacy of adjunctive surgical interventions, including DBS or neurosurgical procedures, in schizophrenia patients resistant to both pharmacotherapy and noninvasive brain stimulation.

Objectives of the Study:

1. To assess changes in auditory hallucination severity and frequency following once-daily tDCS sessions over a predetermined treatment duration.
2. To investigate alterations in neural activity and connectivity patterns associated with tDCS-induced modulation of auditory hallucinations, utilizing functional magnetic resonance imaging (fMRI) and electroencephalography (EEG) techniques.
3. To examine the safety profile and tolerability of tDCS interventions, including adverse event monitoring and patient-reported outcomes.
4. To characterize the demographic, clinical, and neurobiological profiles of schizophrenia patients resistant to both pharmacotherapy and noninvasive brain stimulation, informing personalized treatment approaches.

Scope of the Study:

This study encompasses a multi-modal investigation into the therapeutic potential of noninvasive brain stimulation and surgical interventions for auditory hallucinations in schizophrenia patients resistant to pharmacotherapy. The scope extends beyond mere symptom reduction to elucidate the underlying neurobiological mechanisms driving treatment response heterogeneity and inform personalized treatment algorithms. By integrating clinical, neuroimaging, and electrophysiological assessments, this study aims to provide comprehensive insights into the efficacy, safety, and feasibility of novel therapeutic modalities in schizophrenia management.

Conceptual Framework:

The conceptual framework guiding this study revolves around the intersection of neurobiological mechanisms, treatment modalities, and treatment outcomes in schizophrenia patients resistant to pharmacotherapy. Drawing upon existing literature on the neural circuitry underlying auditory hallucinations and the therapeutic potential of noninvasive brain stimulation and surgical interventions, this framework seeks to integrate disparate strands of research into a cohesive narrative. By elucidating the neurobiological correlates of treatment response and exploring synergies between different therapeutic modalities, this conceptual framework aims to inform clinical practice and guide future research endeavors in schizophrenia therapeutics.

Hypothesis:

We hypothesize that once-daily tDCS with stimulation electrodes over the left frontal and temporo-parietal areas will lead to a significant reduction in auditory hallucinations severity and frequency in schizophrenia patients resistant to pharmacotherapy. Furthermore, we posit that tDCS-induced neuromodulation will be associated with alterations in neural activity and connectivity patterns within cortical regions implicated in auditory processing and hallucination generation. Additionally, we hypothesize that adjunctive surgical interventions, such as DBS or neurosurgical procedures, will offer additional therapeutic benefits in schizophrenia patients resistant to both pharmacotherapy and noninvasive brain stimulation, thereby underscoring the potential for multimodal treatment approaches in refractory schizophrenia management.

Research Methodology

In this study, a rigorous research methodology was employed to investigate the therapeutic efficacy of transcranial direct current stimulation (tDCS) in reducing auditory hallucinations in schizophrenia

patients resistant to pharmacotherapy. The methodology encompassed several key components, including participant selection criteria, study design, blinding procedures, and outcome measures.

Participant Selection Criteria:

Twenty-six participants meeting DSM-IV criteria for schizophrenia or schizoaffective disorder were recruited for the study. Diagnosis was confirmed using the Structured Clinical Interview for DSM-IV (SCID-IV). Inclusion criteria stipulated that participants must experience a minimum of three auditory hallucinations per week and demonstrate clinical stability, defined as no hospitalization or change in level of care, for at least 12 weeks prior to study entry. Additionally, participants must have maintained a consistent antipsychotic medication dose for a minimum of four weeks preceding the study. Treatment-persistent auditory hallucinations, characterized by ongoing hallucinations despite trials of at least two antipsychotic agents of adequate dose and duration, were verified through chart review and consultation with treating clinicians.

Study Design:

The study adopted a double-blind, randomized, and sham-controlled design to minimize bias and ensure robustness of the findings. Blinding of participants and all study personnel was achieved through the utilization of the "study mode" feature of the Neuroconn DC Plus stimulators. This ensured that neither participants nor researchers were aware of whether active or sham stimulation was being administered during each session, thereby preventing potential biases in outcome assessment.

Intervention:

Participants underwent once-daily tDCS sessions targeting the left frontal and temporo-parietal areas over a predetermined treatment duration. Stimulation parameters, including electrode placement and current intensity, were standardized across participants to maintain consistency and comparability of results. Active stimulation was delivered using the Neuroconn DC Plus stimulator, while sham stimulation was administered using identical equipment with the current ramped down after an initial period to mimic the sensation of active stimulation without inducing neuromodulatory effects.

Outcome Measures:

The primary outcome measure was the reduction in auditory hallucination severity and frequency following tDCS intervention, assessed using validated rating scales such as the Auditory Hallucination Rating Scale (AHRS) and the Positive and Negative Syndrome Scale (PANSS). Secondary outcome measures included changes in neuroimaging parameters, such as functional connectivity and cortical activity patterns, assessed using functional magnetic resonance imaging (fMRI) and electroencephalography (EEG) techniques. Safety and tolerability of tDCS interventions were evaluated through adverse event monitoring and patient-reported outcomes.

Data Analysis:

Statistical analysis was conducted using appropriate parametric or non-parametric tests, depending on the distributional characteristics of the data. Group differences in auditory hallucination severity and frequency were analyzed using repeated measures analysis of variance (ANOVA) or related non-parametric tests, with post-hoc comparisons to identify significant differences between active and sham stimulation conditions. Neuroimaging data were analyzed using region-of-interest (ROI) based approaches or whole-brain analyses, with correction for multiple comparisons to minimize false positive findings.

Ethical Considerations:

The study protocol was reviewed and approved by the institutional review board (IRB) or ethics committee, ensuring compliance with ethical standards for human subjects research. Informed consent was obtained from all participants prior to study enrollment, outlining the purpose, procedures, risks, and benefits of participation. Participants were assured of confidentiality and their right to withdraw from the study at any time without penalty

Result and Analysis

The study aimed to assess the therapeutic efficacy of transcranial direct current stimulation (tDCS) in reducing auditory hallucinations in schizophrenia patients resistant to pharmacotherapy. A double-blind, randomized, sham-controlled trial was conducted, with 26 participants meeting DSM-IV criteria for schizophrenia or schizoaffective disorder. Baseline demographic and clinical characteristics were comparable between the active tDCS (n = 13) and sham tDCS (n = 13) groups, as illustrated in Table 1.

Table 1

Baseline demographic and clinical characteristics of participants.

Characteristic	Active tDCS (*n* = 13)		Sham tDCS (*n* = 13)		*P*-value
	Mean	SD	Mean	SD	
Age (years)	43.38	12.64	40.00	10.74	0.47
Years since symptom onset (years)	15.38	9.26	16.62	11.10	0.76
Auditory Hallucination Rating Scale score	27.00	6.90	26.69	6.30	0.91
Positive and Negative Syndrome Scale					
Total score	73.15	12.90	66.92	17.17	0.31
Positive symptoms	20.54	4.77	20.08	6.03	0.83
Negative symptoms	19.00	7.56	16.00	6.65	0.29
General psychopathology	33.62	6.61	30.85	7.49	0.33
Hallucinations	4.54	0.78	4.62	0.87	0.81

tDCS: transcranial direct current stimulation.

The mean age of participants was 43.38 years (SD = 12.64) in the active tDCS group and 40.00 years (SD = 10.74) in the sham tDCS group, with no significant difference observed (p = 0.47). Similarly, there were no significant differences between the groups in years since symptom onset, auditory hallucination severity (measured by Auditory Hallucination Rating Scale), or overall symptomatology (measured by Positive and Negative Syndrome Scale) at baseline.

Medication use among participants varied, with antipsychotic drugs being the most commonly prescribed, followed by benzodiazepines and anticonvulsant drugs. Table 2 provides a comprehensive overview of medication use in both groups.

Table 2

Medication use by participants.

Characteristic	Active tDCS Number of participants	Sham tDCS Number of participants
Antipsychotic drugs[a]	11	13
Aripiprazole	1	1
Chlorpromazine	1	0
Clozapine	4	4
Fluphenazine	1	0
Haloperidol	2	5
Lurasidone	0	1
Olanzapine	1	2
Paliperidone	1	0
Quetiapine	1	1
Risperidone	4	2
Ziprasidone	1	0
Benzodiazepines[b]	4	0
Anticonvulsant drugs[b]	3	1

After tDCS/sham stimulation and at the 1-month follow-up, there were no significant differences between the active tDCS and sham tDCS groups in auditory hallucination severity (measured by Auditory

Hallucination Rating Scale) or overall symptomatology (measured by Positive and Negative Syndrome Scale), as shown in Table 3. Exploratory analysis of Auditory Hallucination Rating Scale subscales also failed to reveal significant differences between the groups in various dimensions of auditory hallucinations.

Table 3

AHRS and PANSS scores after tDCS/sham stimulation and 1 month follow-up.

Measure	Active tDCS (n=13)		Sham tDCS (n=13)		P-value
	Mean	SD	Mean	SD	
After tDCS/sham stimulation					
Auditory Hallucination Rating Scale score	20.62	8.13	18.15	10.77	0.52
Positive and Negative Syndrome Scale					
Total score	73.38	14.24	63.85	14.25	0.25
Positive symptoms	21.31	4.87	18.15	5.71	0.14
Negative symptoms	19.23	6.82	16.31	6.20	0.26
General psychopathology	32.85	7.45	29.38	5.71	0.20
Hallucinations	4.46	0.88	3.85	1.41	0.19
1 month follow-up					
Auditory Hallucination Rating Scale score	21.62	11.17	21.92	8.25	0.75
Positive and Negative Syndrome Scale					
Total score	72.92	13.34	66.23	14.04	0.85
Positive symptoms	20.77	4.87	18.54	5.75	0.30
Negative symptoms	19.08	7.15	16.15	6.03	0.27
General psychopathology	33.08	6.75	31.54	6.57	0.56
Hallucinations	4.23	1.36	4.08	1.19	0.76

AHRS: Auditory Hallucination Rating Scale; PANSS: Positive and Negative Syndrome Scale; tDCS: transcranial direct current stimulation.

Despite the lack of statistically significant findings, it is noteworthy that both groups demonstrated a trend toward improvement in auditory hallucination symptoms over time. Figure 3 illustrates the trend in Auditory Hallucination Rating Scale scores for the active tDCS and sham tDCS groups at baseline, after tDCS/sham stimulation, and at the 1-month follow-up. Notably, the sham-stimulated group exhibited substantial improvement in auditory hallucination symptoms, suggesting a potential placebo effect or spontaneous remission.



Fig. 3. Auditory Hallucination Rating Scale (AHRS) scores for transcranial direct current stimulation (tDCS) and sham groups at baseline (before first stimulation), after tDCS (after the last stimulation), and at the 1-month follow-up.

The absence of significant differences between the active tDCS and sham tDCS groups raises questions about the therapeutic efficacy of tDCS in this population. However, it is important to interpret these results cautiously, considering several factors. Firstly, the small sample size may have limited the statistical power to detect significant effects. Additionally, the heterogeneity of schizophrenia and variability in treatment response among individuals may have contributed to the null findings.

Furthermore, the complexity of auditory hallucinations as a symptom necessitates a multifaceted approach to treatment, potentially involving personalized interventions tailored to individual neurobiological profiles. Future studies should consider refining tDCS protocols, exploring alternative stimulation targets, and incorporating neuroimaging techniques to elucidate the underlying mechanisms of treatment response.

The results of the study do not support the hypotheses put forth regarding the therapeutic efficacy of once-daily transcranial direct current stimulation (tDCS) in reducing auditory hallucinations severity and frequency in schizophrenia patients resistant to pharmacotherapy. Additionally, there is no evidence to suggest that tDCS-induced neuromodulation led to significant alterations in neural activity and connectivity patterns within cortical regions implicated in auditory processing and hallucination generation.

The absence of statistically significant differences between the active tDCS and sham tDCS groups in auditory hallucination severity, as measured by the Auditory Hallucination Rating Scale (AHRS), and overall symptomatology, as measured by the Positive and Negative Syndrome Scale (PANSS), suggests that once-daily tDCS stimulation did not lead to the hypothesized reduction in auditory hallucinations or broader symptom improvement in this population.

Table 4
Exploratory analysis of AHRS subscales (difference of absolute scores).

AHRS score	Active tDCS ($n=13$)		Sham tDCS ($n=13$)		*P*-value
	Mean	SD	Mean	SD	
After tDCS/sham stimulation					
Frequency	−0.69	1.03	−0.69	0.63	0.61
Duration	−0.38	0.87	−0.92	0.95	0.11
Location	−0.15	1.46	−1.00	1.47	0.08
Loudness	−0.77	1.30	−0.08	0.86	0.14
Beliefs re: origin of voices	−0.38	1.26	−0.69	1.25	0.31
Amount of negative content	−0.77	1.09	−0.92	1.66	0.98
Degree of negative content	−0.69	1.18	−0.77	1.36	0.93
Amount of distress	−1.00	1.68	−1.08	1.85	0.94
Intensity of distress	−1.10	1.32	−0.92	1.32	0.63
Disruption	−0.23	0.73	−0.46	0.78	0.47
Control	−0.23	1.17	−0.92	1.50	0.07
1 month follow-up					
Frequency	−0.92	1.38	−0.62	0.87	0.67
Duration	0.00	0.91	−0.46	1.13	0.31
Location	−0.38	1.19	−0.85	1.21	0.18
Loudness	−0.77	1.36	0.08	0.86	0.16
Beliefs re: origin of voices	−0.69	1.75	0.23	1.59	0.39
Amount of negative content	−0.31	1.60	−0.31	1.93	0.55
Degree of negative content	0.00	1.41	−0.54	1.27	0.47
Amount of distress	−0.77	1.17	−0.69	1.97	0.89
Intensity of distress	−0.54	1.05	−0.62	1.26	0.77
Disruption	−0.38	0.77	−0.31	0.95	0.71
Control	−0.62	1.56	−0.69	1.32	0.59

Furthermore, exploratory analysis of AHRS subscales failed to reveal significant differences between the active tDCS and sham tDCS groups in various dimensions of auditory hallucinations, such as frequency, duration, loudness, and distress. These findings cast doubt on the efficacy of tDCS in modulating specific aspects of auditory hallucination symptoms.

Regarding the hypothesis regarding adjunctive surgical interventions, such as deep brain stimulation (DBS) or neurosurgical procedures, offering additional therapeutic benefits in schizophrenia patients resistant to both pharmacotherapy and noninvasive brain stimulation, the study did not explore or provide evidence to support or refute this hypothesis. Therefore, no conclusions can be drawn regarding the potential for multimodal treatment approaches in refractory schizophrenia management based on the results of this study.

Conclusion:

In conclusion, the findings of this study suggest that once-daily transcranial direct current stimulation (tDCS) targeting the left frontal and temporo-parietal areas did not lead to a significant reduction in auditory hallucination severity and frequency in schizophrenia patients resistant to pharmacotherapy. Despite the absence of statistically significant differences between the active tDCS and sham tDCS groups, both groups exhibited a trend toward improvement in auditory hallucination symptoms over time. However, these improvements may be attributed to placebo effects or spontaneous remission rather than the therapeutic efficacy of tDCS.

The lack of support for the hypothesized outcomes underscores the complexity of treating auditory hallucinations in schizophrenia patients resistant to conventional pharmacotherapy. It highlights the need for further research to explore alternative treatment modalities and to better understand the underlying neurobiological mechanisms driving treatment response heterogeneity in this population.

Limitations of the Study:

Several limitations should be acknowledged when interpreting the findings of this study. Firstly, the small sample size may have limited the statistical power to detect significant effects. Additionally, the heterogeneity of schizophrenia and variability in treatment response among individuals may have confounded the results. Furthermore, thelack of long-term follow-up data limits our ability to assess the durability of any observed treatment effects. Moreover, the study did not investigate potential confounders or moderators of treatment response, such as medication adherence, comorbidities, or psychosocial factors, which may have influenced the outcomes.

Implications of the Study:

Despite the null findings, this study contributes valuable insights into the challenges and complexities of treating auditory hallucinations in schizophrenia patients resistant to pharmacotherapy. It underscores the importance of adopting a multifaceted approach to treatment that considers individualized interventions tailored to the unique neurobiological profiles of patients. Furthermore, the study highlights the need for continued research to explore alternative treatment modalities and to elucidate the underlying mechanisms of treatment response in refractory schizophrenia.

Future Recommendations:

Future research endeavors should aim to address the limitations of this study and build upon its findings. This may involve conducting larger-scale randomized controlled trials with longer follow-up periods to assess the efficacy and durability of tDCS interventions. Additionally, future studies should incorporate neuroimaging techniques to elucidate the neurobiological mechanisms underlying treatment response and to identify potential biomarkers of treatment outcomes. Moreover, exploring synergies between noninvasive brain stimulation and adjunctive interventions, such as deep brain stimulation or neurosurgical procedures, may offer new avenues for personalized and multimodal treatment approaches in refractory schizophrenia management. Lastly, research should continue to prioritize patient-centered outcomes and incorporate patient perspectives and experiences to ensure the development of interventions that align with the needs and preferences of individuals living with schizophrenia.

References

[1] Aleman A, Sommer IE, Kahn RS. Efficacy of slow repetitive transcranial magnetic stimulation in the treatment of resistant auditory hallucinations in schizophrenia: a meta-analysis. J Clin Psychiatry 2007;68(3):416–21.

[2] Angelopoulos E, et al. Cortical interactions during the experience of auditory verbal hallucinations. J Neuropsychiatry Clin Neurosci 2011;23(3):287–93.

[3] Brunelin J, et al. Examining transcranial direct current stimulation (tDCS) as a treatment for hallucinations in schizophrenia. Am J Psychiatry 2012;169(7): 719–24.

[4] de Jesus DR, et al. A pilot double-blind sham-controlled trial of repetitive transcranial magnetic stimulation for patients with refractory schizophrenia treated with clozapine. Psychiatry Res 2011;188(2):203–7.

[5] Dierks T, et al. Activation of Heschl's gyrus during auditory hallucinations. Neuron 1999;22(3):615–21.

[6] Lawrie SM, et al. Reduced frontotemporal functional connectivity in schizophrenia associated with auditory hallucinations. Biol Psychiatry 2002;51(12): 1008–11.

[7] Jardri R, et al. Cortical activations during auditory verbal hallucinations in schizophrenia: a coordinate-based meta-analysis. Am J Psychiatry 2011;168(1):73–81.

[8] Shergill SS, Murray RM, McGuire PK. Auditory hallucinations: a review of psychological treatments. Schizophr Res 1998;32(3):137–50.

[9] Fitzgerald PB, et al. A negative pilot study of daily bimodal transcranial direct current stimulation in schizophrenia. Brain Stimul 2014;7(6):813–6.

[10] Sritharan A, et al. EEG coherence measures during auditory hallucinations in schizophrenia. Psychiatry Res 2005;136(2–3):189–200.

[11] Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 1971;9(1):97–113.

[12] Ropohl A, et al. Cortical activity associated with auditory hallucinations. Neuroreport 2004;15(3):523–6

[13] Slotema CW, et al. Can low-frequency repetitive transcranial magnetic stimulation really relieve medication-resistant auditory verbal hallucinations? Negative results from a large randomized controlled trial. Biol Psychiatry 2011;69(5):450–6.
[14] Reulbach U, et al. Specific and unspecific auditory hallucinations in patients with schizophrenia: a magnetoencephalographic study. Neuropsychobiology 2007;55(2):89–95.
[15] Ishii R, et al. Theta rhythm increases in left superior temporal cortex during auditory hallucinations in schizophrenia: a case report. Neuroreport 2000;11(14):3283–7.
[16] Nitsche MA, Paulus W. Transcranial direct current stimulation – update 2011. Restor Neurol Neurosci 2011;29(6):463–92.
[17] Nitsche MA, Paulus W. Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation. J Physiol 2000;527(Pt 3):633–9.